title: Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin.
abstract: We report the solid phase synthesis of a series of 16 linear analogues of the cyclic antagonist of the antidiuretic (V2) and the vasopressor (V1) responses to arginine vasopressin (AVP), d(CH2)5[D-Tyr(Et)2, Val4]AVP(A). Peptide 1, the linear precursor of (A), (CH2)5(SH)-CH2-CO-D-Tyr(Et)-Phe-Val-Asn-Cys-Pro-Arg-Gly-NH2 was modified at position six with alpha-L-aminobutyric acid (Abu) to give peptide 2. Further modifications of the Abu6 analogue (No. 2) at position one by substituting cyclohexylacetic acid (Caa), cyclohexylpropionic acid (Cpa), 1-adamantaneacetic acid (Aaa), phenylacetic acid (Phaa), tert.-butylacetic acid (t-Baa), isovaleric acid (Iva), propionic acid (Pa), L-penicillamine (P), tert.-butoxycarbonyl (Boc) or omitting any substituent at this position, and/or in combination with Arg-NH2(9), Ala-NH2(9), D-Arg8-Arg-NH2(9), and desGly9 modifications yielded the remaining 14 peptides. All 16 peptides were examined for agonistic and antagonistic potencies in AVP V2 and V1 assays in rats. Apart from the Cpa analogue and the analogue lacking any substituent in the 1-position, all exhibit substantial V2 and V1 antagonism. A number are as potent as (A) as V2 antagonists. With an anti-V2 pA2 = 8.11 +/- 0.07, Aaa-D-Tyr(Et)-Phe-Val-Asn-Abu-Pro-Arg-Arg-NH2 (No. 6) is as potent as any cyclic AVP V2 antagonist reported to date. The PaI analogue of No. 6 exhibits promising anti-V2/anti-V1 selectivity. These findings prove conclusively that a ring structure is not a requirement for recognition of or for binding to AVP V2 or V1 receptors. This discovery thus offers a promising new approach to the design of peptide and non-peptide antagonists of AVP and perhaps also to other cyclic peptides such as somatostatin, atrial-natriuretic factor, insulin, and the recently discovered endothelin. Some of these linear antagonists may be of value as pharmacological tools and as therapeutic agents.
authors.affiliation: Medical College of Ohio, Department of Biochemistry, Toledo.
authors.forename: M
authors.initials: M
authors.lastname: Manning
authors.forename: W A
authors.initials: WA
authors.lastname: Klis
authors.forename: M
authors.initials: M
authors.lastname: Kruszynski
authors.forename: J P
authors.initials: JP
authors.lastname: Przybylski
authors.forename: A
authors.initials: A
authors.lastname: Olma
authors.forename: N C
authors.initials: NC
authors.lastname: Wo
authors.forename: G H
authors.initials: GH
authors.lastname: Pelton
authors.forename: W H
authors.initials: WH
authors.lastname: Sawyer
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001127:Arginine Vasopressin / Q000037:antagonists & inhibitors*; D001681:Biological Assay; D007202:Indicators and Reagents; D051381:Rats; D013329:Structure-Activity Relationship; D014667:Vasopressins / Q000138:chemical synthesis* / Q000494:pharmacology
chemical_list: D007202:Indicators and Reagents; D014667:Vasopressins; D001127:Arginine Vasopressin